Misplaced Pages

Evobrutinib: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 15:38, 24 December 2024 editInnerstream (talk | contribs)Autopatrolled, Extended confirmed users4,116 editsNo edit summary← Previous edit Latest revision as of 08:01, 26 December 2024 edit undoCitation bot (talk | contribs)Bots5,450,539 edits Altered issue. Formatted dashes. | Use this bot. Report bugs. | Suggested by Graeme Bartlett | #UCB_toolbar 
(5 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug {{Infobox drug
| drug_name = | drug_name =
Line 4: Line 5:
| type = <!-- empty --> | type = <!-- empty -->
| image = Evobrutinib.svg | image = Evobrutinib.svg
⚫ | width =
| alt = | alt =
| caption = | caption =
⚫ | image2 =
⚫ | width2 =
| alt2 =
| caption2 =
| imageL =
| widthL =
| altL =
| imageR =
| widthR =
| altR =
| captionLR =

<!-- Clinical data --> <!-- Clinical data -->
| pronounce = | pronounce =
Line 11: Line 25:
| Drugs.com = | Drugs.com =
| MedlinePlus = | MedlinePlus =
| licence_CA =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| licence_EU =
| DailyMedID =
| licence_US =
| pregnancy_AU =
| pregnancy_AU_comment = | pregnancy_AU_comment =
| pregnancy_category= | pregnancy_category=
| dependency_liability =
| addiction_liability =
| routes_of_administration = | routes_of_administration =
| class =
| ATCvet = | ATCvet =
| ATC_prefix = <!-- 'none' if uncategorised --> | ATC_prefix =
| ATC_suffix = | ATC_suffix =
| ATC_supplemental =

<!-- Legal status --> <!-- Legal status -->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
Line 38: Line 61:
| legal_UN_comment = | legal_UN_comment =
| legal_status = Investigational | legal_status = Investigational

<!-- Pharmacokinetic data --> <!-- Pharmacokinetic data -->
| bioavailability = | bioavailability =
Line 47: Line 71:
| duration_of_action= | duration_of_action=
| excretion = | excretion =

<!-- Identifiers --> <!-- Identifiers -->
| CAS_number = 1415823-73-2 | CAS_number = 1415823-73-2
| CAS_supplemental =
| PubChem = 71479709 | PubChem = 71479709
| PubChemSubstance =
⚫ | UNII = ZA45457L1K
| KEGG = D12467 | IUPHAR_ligand =
| DrugBank = DB15170 | DrugBank = DB15170
| ChemSpiderID = 58827807
| UNII = ZA45457L1K
| KEGG = D12467
| ChEBI =
| ChEMBL = 4072833
| NIAID_ChemDB =
| PDB_ligand =
| synonyms =

<!-- Chemical and physical data --> <!-- Chemical and physical data -->
| IUPAC_name = <nowiki>1-amino]methyl]piperidin-1-yl]prop-2-en-1-one</nowiki>
⚫ | IUPAC_name =
| C=25 | H=27 | N=5 | O=2
⚫ | smiles = C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N
| molecular_weight =
⚫ | C = 25 | H = 27 | N = 5 | O = 2
⚫ | SMILES = C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N
| Jmol =
| StdInChI = InChI=1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29)
| StdInChI_comment =
| StdInChIKey = QUIWHXQETADMGN-UHFFFAOYSA-N
| density =
| density_notes =
| melting_point =
| melting_high =
| melting_notes =
| boiling_point =
| boiling_notes =
| solubility =
| sol_units =
| specific_rotation =
}} }}


'''Evobrutinib''' is an experimental drug being studied for the treatment of ] and ].<ref>{{cite web | url = https://adisinsight.springer.com/drugs/800041955 | title = Evobrutinib | publisher = AdisInsight }}</ref><ref>{{cite journal | doi = 10.1177/13524585241234783 | title = Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study | date = 2024 | last1 = Montalban | first1 = Xavier | last2 = Piasecka-Stryczynska | first2 = Karolina | last3 = Kuhle | first3 = Jens | last4 = Benkert | first4 = Pascal | last5 = Arnold | first5 = Douglas L. | last6 = Weber | first6 = Martin S. | last7 = Seitzinger | first7 = Andrea | last8 = Guehring | first8 = Hans | last9 = Shaw | first9 = Jamie | last10 = Tomic | first10 = Davorka | last11 = Hyvert | first11 = Yann | last12 = Harlow | first12 = Danielle E. | last13 = Dyroff | first13 = Martin | last14 = Wolinsky | first14 = Jerry S. | journal = Multiple Sclerosis Journal | volume = 30 | issue = 4–5 | pages = 558–570 | pmid = 38436271 | pmc = 11080380 }}</ref><ref>{{cite journal | doi = 10.1016/S1474-4422(24)00328-4 | title = Safety and efficacy of evobrutinib in relapsing multiple sclerosis (EvolutionRMS1 and evolutionRMS2): Two multicentre, randomised, double-blind, active-controlled, phase 3 trials | date = 2024 | last1 = Montalban | first1 = Xavier | last2 = Vermersch | first2 = Patrick | last3 = Arnold | first3 = Douglas L. | last4 = Bar-Or | first4 = Amit | last5 = Cree | first5 = Bruce A C. | last6 = Cross | first6 = Anne H. | last7 = Kubala Havrdova | first7 = Eva | last8 = Kappos | first8 = Ludwig | last9 = Stuve | first9 = Olaf | last10 = Wiendl | first10 = Heinz | last11 = Wolinsky | first11 = Jerry S. | last12 = Dahlke | first12 = Frank | last13 = Le Bolay | first13 = Claire | last14 = Shen Loo | first14 = Li | last15 = Gopalakrishnan | first15 = Sathej | last16 = Hyvert | first16 = Yann | last17 = Javor | first17 = Andrija | last18 = Guehring | first18 = Hans | last19 = Tenenbaum | first19 = Nadia | last20 = Tomic | first20 = Davorka | journal = The Lancet Neurology | volume = 23 | issue = 11 | pages = 1119–1132 | pmid = 39307151 }}</ref> It is an ] of ].<ref>{{cite web | url = https://mstrust.org.uk/a-z/evobrutinib | title = Evobrutinib | publisher = Multiple Sclerosis Trust }}</ref> '''Evobrutinib''' is an experimental drug being studied for the treatment of ] and ].<ref>{{cite web | url = https://adisinsight.springer.com/drugs/800041955 | title = Evobrutinib | work = AdisInsight | publisher = Springer Nature Switzerland AG }}</ref><ref>{{cite journal | vauthors = Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M, Wolinsky JS | title = Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study | journal = Multiple Sclerosis | volume = 30 | issue = 4–5 | pages = 558–570 | date = April 2024 | pmid = 38436271 | pmc = 11080380 | doi = 10.1177/13524585241234783 }}</ref><ref>{{cite journal | vauthors = Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BA, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D | title = Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials | journal = The Lancet. Neurology | volume = 23 | issue = 11 | pages = 1119–1132 | date = November 2024 | pmid = 39307151 | doi = 10.1016/S1474-4422(24)00328-4 }}</ref> It is an ] of ].<ref>{{cite web | url = https://mstrust.org.uk/a-z/evobrutinib | title = Evobrutinib | publisher = Multiple Sclerosis Trust }}</ref>


==References== ==References==
Line 70: Line 120:
] ]
] ]
]

Latest revision as of 08:01, 26 December 2024

Pharmaceutical compound
Evobrutinib
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • 1-amino]methyl]piperidin-1-yl]prop-2-en-1-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC25H27N5O2
Molar mass429.524 g·mol
3D model (JSmol)
SMILES
  • C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N
InChI
  • InChI=InChI=1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29)
  • Key:QUIWHXQETADMGN-UHFFFAOYSA-N

Evobrutinib is an experimental drug being studied for the treatment of encephalomyelitis and multiple sclerosis. It is an inhibitor of Bruton's tyrosine kinase.

References

  1. "Evobrutinib". AdisInsight. Springer Nature Switzerland AG.
  2. Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, et al. (April 2024). "Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study". Multiple Sclerosis. 30 (4–5): 558–570. doi:10.1177/13524585241234783. PMC 11080380. PMID 38436271.
  3. Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BA, Cross AH, et al. (November 2024). "Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials". The Lancet. Neurology. 23 (11): 1119–1132. doi:10.1016/S1474-4422(24)00328-4. PMID 39307151.
  4. "Evobrutinib". Multiple Sclerosis Trust.
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Evobrutinib: Difference between revisions Add topic